JPWO2022067347A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022067347A5 JPWO2022067347A5 JP2023519178A JP2023519178A JPWO2022067347A5 JP WO2022067347 A5 JPWO2022067347 A5 JP WO2022067347A5 JP 2023519178 A JP2023519178 A JP 2023519178A JP 2023519178 A JP2023519178 A JP 2023519178A JP WO2022067347 A5 JPWO2022067347 A5 JP WO2022067347A5
- Authority
- JP
- Japan
- Prior art keywords
- her2
- mutation
- subject
- administered
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063084481P | 2020-09-28 | 2020-09-28 | |
| US63/084,481 | 2020-09-28 | ||
| US202063113245P | 2020-11-13 | 2020-11-13 | |
| US63/113,245 | 2020-11-13 | ||
| US202163222335P | 2021-07-15 | 2021-07-15 | |
| US63/222,335 | 2021-07-15 | ||
| PCT/US2021/071606 WO2022067347A1 (en) | 2020-09-28 | 2021-09-27 | Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023543261A JP2023543261A (ja) | 2023-10-13 |
| JPWO2022067347A5 true JPWO2022067347A5 (https=) | 2024-10-07 |
| JP2023543261A5 JP2023543261A5 (https=) | 2024-10-07 |
Family
ID=78464001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519178A Withdrawn JP2023543261A (ja) | 2020-09-28 | 2021-09-27 | ツカチニブを抗ｈｅｒ２抗体と組み合わせて用いてｈｅｒ２変化により駆動される固形腫瘍を処置する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230372342A1 (https=) |
| EP (1) | EP4217400A1 (https=) |
| JP (1) | JP2023543261A (https=) |
| KR (1) | KR20230078705A (https=) |
| CN (1) | CN116437924A (https=) |
| AU (1) | AU2021349384A1 (https=) |
| CA (1) | CA3197165A1 (https=) |
| IL (1) | IL301405A (https=) |
| MX (1) | MX2023003406A (https=) |
| WO (1) | WO2022067347A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023230429A1 (en) * | 2022-05-22 | 2023-11-30 | Seagen Inc. | Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody |
| TW202502352A (zh) | 2023-03-10 | 2025-01-16 | 美商思進公司 | 使用抗ｈｅｒ２抗體－藥物結合物及ｈｅｒ２激酶抑制劑治療癌症之方法 |
| TW202541808A (zh) | 2023-12-20 | 2025-11-01 | 德商百靈佳殷格翰國際股份有限公司 | 抗癌組合治療 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4683203A (en) | 1984-04-14 | 1987-07-28 | Redco N.V. | Immobilized enzymes, processes for preparing same, and use thereof |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
| US5413197A (en) | 1994-03-14 | 1995-05-09 | Baer; Larry G. | Parking brake valve |
| EP3615695A1 (en) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2 mutations in the transmebrane or juxtamembrane domain |
| CA3060407A1 (en) * | 2017-04-28 | 2018-11-01 | Seattle Genetics, Inc. | Treatment of her2 positive cancers |
| TW202042820A (zh) * | 2019-01-28 | 2020-12-01 | 美商西雅圖遺傳學股份有限公司 | 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法 |
-
2021
- 2021-09-27 US US18/027,557 patent/US20230372342A1/en active Pending
- 2021-09-27 EP EP21801380.3A patent/EP4217400A1/en active Pending
- 2021-09-27 CN CN202180075987.1A patent/CN116437924A/zh active Pending
- 2021-09-27 IL IL301405A patent/IL301405A/en unknown
- 2021-09-27 AU AU2021349384A patent/AU2021349384A1/en not_active Abandoned
- 2021-09-27 WO PCT/US2021/071606 patent/WO2022067347A1/en not_active Ceased
- 2021-09-27 MX MX2023003406A patent/MX2023003406A/es unknown
- 2021-09-27 CA CA3197165A patent/CA3197165A1/en active Pending
- 2021-09-27 JP JP2023519178A patent/JP2023543261A/ja not_active Withdrawn
- 2021-09-27 KR KR1020237012912A patent/KR20230078705A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dziadziuszko et al. | Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP) | |
| Prelaj et al. | Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program | |
| Chung et al. | Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers | |
| Ichihara et al. | Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non–small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001 | |
| Burstein et al. | A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer | |
| WO2020230091A1 (en) | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors | |
| CN112996534B (zh) | 结合间变性淋巴瘤激酶抑制剂进行egf/egfr通路抑制的方法和组合物 | |
| US20230310455A1 (en) | Combination therapies for treatment of her2 cancer | |
| TWI868714B (zh) | 用於治療非小細胞肺癌之奧希替尼 | |
| TW202015738A (zh) | 藉由投與抗ｈｅｒ２抗體－藥物結合物之ｈｅｒ２突變型癌症之治療 | |
| AU2010236818B2 (en) | Combination therapy using an anti-EGFR agent(s) and IGF-1R specific inhibitors | |
| Garon et al. | A brief report of durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: outcomes by tumor PD-L1 expression in the phase 3 POSEIDON study | |
| Zhou et al. | Efficacy of pyrotinib with/without trastuzumab in treatment-refractory, HER2-positive metastatic colorectal cancer: result from a prospective observational study | |
| EP3968985A1 (en) | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors | |
| Lara et al. | Phase 1 study of ceritinib combined with trametinib in patients with advanced ALK-or ROS1-positive NSCLC | |
| JPWO2022067347A5 (https=) | ||
| Kinehara et al. | Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer | |
| EP4153783A1 (en) | Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma | |
| US20250135023A1 (en) | Treatment of hr+/her2- breast cancer using sacituzumab govitecan | |
| Aoki et al. | An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX for HER2-low gastroesophageal adenocarcinoma | |
| Sawada et al. | Development of HER2-targeted therapies for gastrointestinal cancer | |
| Curigliano | Peter Schmid, Mafalda Oliveira, Joyce O’Shaughnessy, Massimo Cristofanilli, Stephanie L. Graff, Seock-Ah Im, Sherene Loi, Shigehira Saji, Shusen Wang, David W. Cescon, Tina Hovey, Agata Nawrot, Karson Tse, Petra Vukovic and | |
| O'Shaughnessy et al. | TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer | |
| Costa et al. | Future roles of lapatinib in ErbB2-positive breast cancer: adjuvant and neoadjuvant trials | |
| TW202206073A (zh) | 用於治療癌症之劑量方案 |